ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) shares have had a really impressive month, gaining 77% after a shaky period beforehand. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 32% in the last twelve months.
Following the firm bounce in price, ImmuneOnco Biopharmaceuticals (Shanghai) may be sending strong sell signals at present with a price-to-sales (or “P/S”) ratio of 45.6x, when you consider almost half of the companies in the Biotechs industry in Hong Kong have P/S ratios under 12.1x and even P/S lower than 5x aren’t out of the ordinary. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly elevated P/S.
